Reuters logo
BRIEF-GlaxoSmithKline announces mepolizumab phase III results in patients with COPD
2017年9月12日 / 早上8点07分 / 8 天前

BRIEF-GlaxoSmithKline announces mepolizumab phase III results in patients with COPD

Sept 12 (Reuters) - GlaxoSmithKline Plc

* ANNOUNCES PHASE III RESULTS PUBLISHED IN NEJM OF MEPOLIZUMAB IN PATIENTS WITH EOSINOPHILIC COPD AT RISK OF EXACERBATIONS

* REGULATORY FILINGS PLANNED FOR 2017

* REDUCTION IN FREQUENCY OF EXACERBATIONS OBSERVED IN METREX STUDY WAS STATISTICALLY SIGNIFICANT

* ‍FOR SECONDARY ENDPOINTS, STATISTICALLY SIGNIFICANT INCREASE IN TIME TO FIRST MODERATE AND SEVERE EXACERBATION IN METREX

* NO NEW SAFETY CONCERNS TO KNOWN SAFETY PROFILE OF MEPOLIZUMAB WERE IDENTIFIED ON REVIEW OF DATA FROM THE STUDIES Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below